The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.
Human research record. Critical care medicine, 2022.
- Human
- 2022
Authorship
Exact sentences from the abstract. No machine-written text is on this page. No person reviewed it.
Source: the abstract of PMID 36044317. Checked Verification: Evidence verified by machine against declared source
This study and its findings belong to the authors cited. Defiance International, a supplier of chemical sequences for research use, keeps this record and makes no claim from its findings.
Evidence verified by machine against declared source
Key facts
- Design
- Not reported
- System
- Human
- Scale
- In December 2020, the sponsor submitted a modified protocol and statistical analysis plan to FDA in consultation with the IRB and DMC extending the trial to 60 days of observation and a sample size of 198 subjects.
- Comparator
- Present
- Journal
- Critical care medicine
- Year
- 2022
- PMID
- 36044317
- Verification
- Evidence verified by machine against declared source The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
- Full-text availability
- Abstract only
Technical summary
Research question
The study aims to determine whether Aviptadil (synthetic VIP) can improve survival and recovery in patients with COVID-19 respiratory failure compared with placebo and demonstrate biological effects in such patients.
Study design
A multicenter, placebo-controlled trial.
Participants or experimental system
A total of 196 patients with COVID-19 respiratory failure.
Study scale
In December 2020, the sponsor submitted a modified protocol and statistical analysis plan to FDA in consultation with the IRB and DMC extending the trial to 60 days of observation and a sample size of 198 subjects.
Comparator
Participants were randomized 2:1 to receive 3 days of IV Aviptadil or placebo.
Outcomes examined
The key secondary end point was survival at 60-day posttreatment, as ascertained by study-site personnel.
Key findings
There was, however, a statistically significant two-fold odds of improved survival (OR, 2.0; 95% CI, 1.1–3.9) at 60 days (p = 0.035).
Not reported in the declared source: Methods, Intervention or exposure.
Limitations and uncertainty
Another limitation was the randomization imbalance in baseline ventilation status as determined by the NIAID score.
Cite
Cite the study
The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.
Youssef JG, Lavin P, Schoenfeld DA et al. Critical care medicine. 2022. PMID 36044317
The study and its abstract belong to their authors and publisher. Cite them for anything the study found.
Report an error
If a sentence on this record does not match the abstract, tell us which one. A report starts an automatic re-check by machine. No person reads the record first.
The form takes a sentence and your note. It asks for no name and no address, and we store neither. Do not put personal details in the note.
The report form runs in the interactive page. Open this record with scripts enabled to send a report.
Corrections on this record
No correction has been recorded for this record.
Method sheet
No machine-drafted summary is published on this record. Any section shown is the abstract’s own sentence, printed as issued.